跳至主要内容
临床试验/NCT06975813
NCT06975813尚未招募2 期

Efficacy of Isolated Masseter Versus Masseter- Sternocleidomastoid Trigger Points Injection by Magnesium Sulfate for Myofacial Pain

Fayoum University0 个研究点目标入组 30 人开始时间: 2025年6月1日最近更新:
干预措施
相关药物

试验速览

阶段
2 期
状态
尚未招募
入组人数
30
主要终点
muscle pain

研究概览

简要总结

The patients will be randomly assigned to one of the two groups according to the treatment method: group I (masseter group) and group II (masseter &sternocleidomastoid group) where each patient will be injected 0.5ml in each trigger point (TrPs) of magnesium sulphate according to the treatment group by the same operator. The treatment method for TrPs will be the primary predictor variable. Patients will be examined at the following intervals: during diagnosis, 1-month, 3-months, and 6-months post-injection. The participated patients will be assessed using pain score measured on a 10-point visual analogue scale (VAS), the 0 indicating no pain and 10 indicating the worst pain ever

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • definite diagnosis of myofascial pain
  • presence of one or more unilateral or bilateral trigger points in the masseter muscle and sternocleidomastoid muscle;
  • no history of any invasive procedures of the related masseter muscle.

排除标准

  • any painful conditions (other than myofascial trigger points) affecting the orofacial region
  • any systemic diseases that could masticatory function (e.g., rheumatoid arthritis and epilepsy);
  • pregnancy and lactation

研究组 & 干预措施

masseter muscle

Active Comparator

干预措施: masseter muscle (Drug)

masseter and sternocleidomastoid muscles

Experimental

干预措施: masseter and sternocleidomastoid muscle (Drug)

结局指标

主要结局

muscle pain

时间窗: 6 months

by visual analogue scal

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shaimaa Mohsen

associate professor

Fayoum University

相似试验